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A Case of Lamotrigine-Induced Excessive 
Involuntary Eye Blinking
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Department of Neurology, Pochon CHA University, College of Medicine, Sungnam, Korea
A wide variety of movement disorders can be induced by the administration of antiepileptic drugs. A 44-year-old 
female was admitted with involuntary excessive eye blinking that manifested 5 months after beginning the admini-
stration of lamotrigine for control of complex partial and secondarily generalized seizures. The involuntary eye 
blinking persisted while taking lamotrigine, and disappeared 1 month after the cessation of lamotrigine. The 
development of atypical involuntary eye blinking in this case may have resulted from the inhibition of excitatory 
neurotransmitters by lamotrigine, which led to secondary dysfunction of the dopaminergic system.
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Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)- 
1,2,4- triazine; LTG) is one of the most commonly used 
broad-spectrum antiepileptic drugs (AEDs). In vitro phar-
macological studies suggest that LTG inhibits voltage- 
sensitive sodium channels, thereby stabilizing neuronal 
membranes and consequently modulating the presynaptic 
release of excitatory amino acid transmitters (e.g., glu-
tamate and aspartate).
1 Common side effects of LTG are 
skin rash, dizziness, headache, ataxia, nausea, vomiting, 
and diplopia. There are several case reports of the de-
velopment of involuntary movement disorders including 
chorea and tic disorder after LTG treatment.
2,3 However, 
LTG-induced involuntary eyelid movement disorder is 
extremely rare. Here we present a case with LTG- 
induced excessive involuntary eye blinking.
CASE REPORT
A 44-year-old female presented with excessive in-
voluntary eye blinking with a 5-month history. She had 
no family history of epilepsy or movement disorder. 
She had a history of febrile convulsion with a frequency 
of 5 or 6 times per year during infancy. When she was 
7 years old, she was diagnosed with epilepsy and started 
medication with AEDs. Semiology revealed complex 
partial seizures composed of vacant staring and auto-
matism with occasionally secondary generalized tonic- 
clonic seizures. She was recently treated with pheno-
barbital (maintenance dose of 60 mg/day) in combi-
nation with primidone (250 mg/day) at a local clinic, 
which decreased her seizure frequency to twice yearly. 
Five months prior to visiting our clinic, she was treated 
with LTG (Lamictal
® at 25 mg/day) following dis-
continuation of previous AEDs at another hospital. The 
dosage of LTG was increased slowly to 200 mg/day, 
and her seizures were well controlled. However, 5 
months after LTG treatment, an involuntary eye blinking Journal of Clinical Neurology: Vol. 3, No. 2, 2007
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Figure 1. Electroencephalography study shows no epileptiform discharges during eye blinking. On simultaneous electro-
myography (EMG) attached to surface electrodes on both eyelid muscles, the frequency of eyeblinking after cessation of 
lamotrigine was normalized to 0.5 times/second (B) compared with on medication of lamotrigine (1.7 times/second) (A)
developed. No other medication (including digestives) 
was prescribed and no procedure was performed when 
this symptom developed. She visited our hospital 
because of persistent excessive involuntary eye blink-
ing for the previous 5 months.
The initial neurological examination revealed ex-
cessive eye blinking with a frequency of about twice per 
second that was not accompanied with blepharospasm. 
She could not voluntarily control her eye blinking, and 
the frequency of eye blinking did not change during ex-
traocular movement at any direction or during con-
versation. Cranial nerve function including pupil light 
reflex and extraocular movement, facial motor and 
sensory functions, corneal reflex, and glabella reflex 
were all normal. Other neurologic examinations pro-
duced normal results. Video monitoring combined with 
electroencephalography (EEG) with extra electrodes 
1 cm lateral to both orbits showed normal findings 
without epileptiform discharges. Eye blinking on electro-
myography (EMG) continued at a frequency of 1.7 
times/second during EEG monitoring (Fig. 1-A). Facial 
nerve conduction and the blink reflex were normal. We 
changed LTG to topiramate (Topamax
® at 100 mg/day), 
with the dosage subsequently being increased to 200 
mg/day. The excessive involuntary eyelid blinking im-
proved gradually 1 month after the cessation of LTG. 
We changed topiramate to valproic acid (Depakote ER
® 
at 500 mg/day) due to intolerable side effects of a poor 
appetite and tingling sensation. After treatment of 
valproic acid and cessation of LTG, the episodes of 
involuntary eye blinking resolved completely without an 
seizures. Repeated EEG monitoring revealed that the 
frequency of eye blinking had decreased (to once every 
2 seconds) (Fig. 1-B), and excessive eye blinking was 
absent at a 7-month follow-up.
DISCUSSION
Eye blinking is fundamental to corneal wetting and 
eye protection, and consists of two physiologic com-
ponents: (1) inhibition of sustained activity of the levator 
palpebrae superioris muscles and (2) concurrent activa-
tion of the orbicularis oculi muscles.
4 The eye-blinking 
signal is generated in the reticular formation of the 
rostral pons and regulated by the substantia nigra, 
superior colliculus, occipital cortex via the lateral 
geniculate body, and optic radiation. The thalamus and 
cerebellum are also involved in the production of eye 
blinking.
5 An abnormal eye blinking rate is observed in 
many diseases involving the central nervous system. The 
rate of eye blinking is usually decreased in Parkinson’s 
disease, but increased in schizophrenia, Huntington’s 
disease, and blepharospasm.
5 In depression, eye blinking 
can be either increased or decreased.
5
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deficits except for the excessive involuntary eye blink-
ing, and this was not induced by seizure based on the 
EEG findings being normal during excessive eye blink-
ing. An association with depression was unlikely because 
there was no evidence of mood disorder. Excessive 
involuntary eye blinking began in our patient after 5 
months of administration with LTG and disappeared 
completely after the cessation of LTG, which indicates 
a close association between the condition and LTG. 
Various involuntary movements as side effects of 
AEDs have been reported. Tremor (postural or kinetic) 
is one of common side effects of AEDs such as val-
proic acid and phenytoin.
6,7  Chorea was reported in 
several patients receiving phenytoin or valproic acid.
8,9 
LTG-induced eyelid movement disorder is extremely 
rare. Verma et al.
10 reported a patient who developed 
blepharospasm 4 months after beginning the admini-
stration of LTG, with it disappearing 1 month after the 
cessation of LTG. However, to our knowledge, in-
voluntary eye blinking associated with LTG has not 
been reported previously.
Many drug-induced movement disorders are related to 
an enhanced dopaminergic system. Neuroleptics are re-
presentative of the drugs that induce abnormal move-
ment, acting on dopamine receptors directly and leading 
to postsynaptic dopamine supersensitivity and a post-
synaptic increase in the number of dopamine receptors.
5 
The mechanism of LTG-induced involuntary movement 
has been unclear. LTG does not directly affect striatal 
dopamine receptors, and hence the pathophysiological 
mechanism of LTG-induced involuntary movement 
differs from that induced by neuroleptics. One possible 
explanation is that LTG inhibits presynaptic excitatory 
neurotransmitters, which induce the striatal dopaminergic 
system secondarily. For example, amantadine, a subtype 
N-methyl-D-aspartate receptor (NMDA) blocker, exerts 
antiparkinsonian effects via inhibition of NMDA re-
ceptors, which secondarily facilitates the presynaptic 
release of striatal dopamine. Although LTG has no effect 
of NMDA receptor blockade, it may indirectly influence 
the dopaminergic system by inhibiting some types of 
excitatory neurotransmitters. Zipp et al.
11 reported five 
patients with Parkinson’s disease who were successfully 
treated with LTG, which suggests that LTG can in-
fluence the dopaminergic system indirectly via an 
unknown mechanism, even though it is not associated 
with the direct inhibition of dopamine or glutamate 
receptors. Further investigations are needed to clarify 
the exact pathophysiological mechanism of LTG-in-
duced involuntary movement.
In conclusion, we report a case of LTG-induced 
excessive involuntary eye blinking. The results presented 
here indicate that unrepresentative side effects such as 
involuntary eye blinking should be considered when 
LTG is administered.
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